Company: GIFLF
Filing Date: 2025-02-26
Form Type: 6-K
Source: 0001104659-25-017501
Chunk: 45

Company: Grifols SA
Filing Date: 2025-02-26
Form: 6-K
Chunk 45
---
 the last remaining 6 US plasma collection                 
 centres (the "Group 4 Centres") from Immunotek, for a purchase price of approximately US$62,428,000, which                     
 payment obligation matures on 2 January 2026 (as foreseen in the original Immunotek Collaboration Agreement). As               
 a result, Grifols has recognised a short-term liability in the 2025 financial year for the amount of the (deferred)            
 purchase price of the Group 4 Centres.                                                                                         
 Such deferral of the payment obligation has been documented in a promissory note between Biomat Holdings LLC,                  
 as issuer, and Immunotek, as Noteholder, for an amount of US$69,343,084 (the "Promissory Note") (which includes                
 management fees of approximately US$ 7 million), maturing on 2 January 2026 and with no interest accrual. The                  
 Group 4 Centres act as collateral of the Promissory Note and (following the same guarantee provided by Grifols S.A.            
 under the Immunotek Collaboration Agreement) the Promissory Note is guaranteed by Grifols, S.A.                                
 Now therefore, and following the acquisition of the Group 3 Centres and the Group 4 Centres, Grifols has obtained              
 control of the 14 centres on their acquisition date in 2025 (which had previously been considered within a joint               
 operation) and now fully owns and will manage (from 1 May 2025), through its subsidiary Biomat Holdings LLC, all               
 of the 28 US plasma collection centres developed by Immunotek under the Immunotek Collaboration Agreement.                     
 The collaboration with Immunotek has now been terminated (although Immunotek will continue to manage the Group                 
 4 Centres until 30 April 2025 under a transitional services agreement), and GBNA is no longer a party in the joint             
 venture company, Biotek America LLC.                                                                                           
 Grifols has applied the requirements for a business combination carried out in stages. However, considering that (i)           
 Grifols' effective participation in the joint operation is null and void and (ii) all of the assets and liabilities related to 
 the joint operation are already recognized in the consolidated financial statements, the difference between the                
 consideration paid and the fair value of the assets and liabilities, which does not differ from their carrying amount,         
 has been recognized as provisional goodwill at the date of acquisition.